ZEISS CLARUS 700 Receives NMPA Approval in China
JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation.
"ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow."
"Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China.
Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them.
More information about the CLARUS® 700 from ZEISS can be found here.
1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). https://doi.org/10.1038/s41598-023-43947-5
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.
Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.med@zeiss.com
Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: press.med@zeiss.com
www.zeiss.com/newsroom
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).
The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
View original content to download multimedia:https://www.prnewswire.com/news-releases/zeiss-clarus-700-receives-nmpa-approval-in-china-302473929.html
SOURCE Carl Zeiss Meditec AG
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/05/c8118.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
10 minutes ago
- Hamilton Spectator
TikTok CEO asks to meet with industry minister over shutdown order
OTTAWA - The CEO of TikTok is asking Industry Minister Mélanie Joly for an urgent meeting about the federal government's order directing the company to shut down its Canadian operations. Shou Chew wrote to Joly on July 2 asking for an in-person meeting within two weeks, according to a letter obtained by The Canadian Press. Chew argued that order was made in different circumstances, when it looked like the United States was going to ban TikTok. 'There is no upside to this outdated and counterproductive government order, which was issued under a different government and in a different era, and which doesn't reflect today's reality,' the letter says. In November, Ottawa ordered the dissolution of TikTok's Canadian business following a national security review of ByteDance Ltd., the Chinese company behind the social media platform. While TikTok has been told to wind down its Canadian operations, the app will continue to be available to Canadians. Chew argued going ahead with that November directive would make Canada an outlier among its allies, including other countries that are part of the Five Eyes intelligence-sharing alliance. He said the order appeared to be based on 'assumptions about TikTok's future in the United States which no longer hold true.' Canada launched its national security review in the fall of 2023 but did not disclose it until March 2024, when the U.S. House of Representatives passed a bill to ban TikTok if ByteDance did not divest its stake. But in June, U.S. President Donald Trump extended the deadline to ban TikTok in the U.S. for a third time. In the July 2 letter, Chew said that without Joly's intervention, the company would soon have to fire more than 350 employees in Canada, stop its direct investment in Canada and cut support for Canadian creators and culture. 'The wind-up process is rapidly approaching a critical juncture,' he wrote. On July 7, TikTok said it was pulling out as a sponsor of several Canadian arts institutions, including the Juno Awards and the Toronto International Film Festival. A spokesperson for Joly did not answer questions about whether the minister has responded to the letter or plans to meet with Chew. TikTok is challenging the shutdown order in Federal Court. It launched a legal challenge in December, arguing the government ordered 'measures that bear no rational connection to the national security risks it identifies.' Ottawa's national security review was carried out through the Investment Canada Act, which allows the government to investigate any foreign investment with the potential to harm national security. When he was industry minister, François-Philippe Champagne said the government was taking action to address 'specific national security risks.' He didn't specify what those risks are. Privacy and safety concerns about TikTok and ByteDance have focused on Chinese national security laws that compel organizations in the country to assist with intelligence gathering. Chew said no evidence has been presented to show that TikTok is a security threat to Canada and the government has not been interested in discussing solutions. He said the government's concerns could be addressed through measures such as enhanced data security protocols and additional transparency and oversight measures. The shutdown order would leave TikTok available to its 14 million users in Canada, Chew said in the letter. But the company would 'no longer have a presence or representatives within Canada's jurisdiction,' he added. He said the company's Canadian employees have appeared at Parliamentary committees, engaged with regulators, trained Canadian law enforcement on how to submit lawful access requests and worked with Elections Canada during the federal election. 'TikTok maintaining a presence in Canada means there is a local team who is accountable to Canadian policy-makers and authorities,' he wrote. This report by The Canadian Press was first published July 14, 2025.
Business Wire
an hour ago
- Business Wire
Exact Sciences Schedules Second Quarter 2025 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details A replay of the webcast will be available at The webcast, conference call, and replay are open to all interested parties. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard ® and Oncotype DX ®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit follow @ExactSciences on X, or connect on LinkedIn and Facebook.
CNBC
3 hours ago
- CNBC
Alibaba-backed Moonshot releases new Kimi AI model that beats ChatGPT, Claude in coding — and it costs less
BEIJING — The latest Chinese generative artificial intelligence model to take on OpenAI's ChatGPT is offering coding capabilities — at a lower price. Alibaba-backed startup Moonshot released on late Friday night its Kimi K2 model: a low-cost, open source large language model — the two factors that underpinned China-based DeepSeek's industry disruption in January. Open-source technology provides source code access for free, an approach that few U.S. tech giants have taken, other than Meta and Google to some extent. Coincidentally, OpenAI CEO Sam Altman announced early Saturday that there would be an indefinite delay of its first open-source model yet again due to safety concerns. OpenAI did not immediately respond to a CNBC request for comment on Kimi K2. One of Kimi K2's strengths is in writing computer code for applications, an area in which businesses see potential to reduce or replace staff with generative AI. OpenAI's U.S. rival Anthropic focused on coding with its Claude Opus 4 model released in late May. In its release announcement on social media platforms X and GitHub, Moonshot claimed Kimi K2 surpassed Claude Opus 4 on two benchmarks, and had better overall performance than OpenAI's coding-focused GPT-4.1 model, based on several industry metrics. "No doubt [Kimi K2 is] a globally competitive model, and it's open sourced," Wei Sun, principal analyst in artificial intelligence at Counterpoint, said in an email Monday. "On top of that, it has lower token costs, making it attractive for large-scale or budget-sensitive deployments," she said. The new K2 model is available via Kimi's app and browser interface for free unlike ChatGPT or Claude, which charge monthly subscriptions for their latest AI models. Kimi is also only charging 15 cents for every 1 million input tokens, and $2.50 per 1 million output tokens, according to its website. Tokens are a way of measuring data for AI model processing. In contrast, Claude Opus 4 charges 100 times more for input — $15 per million tokens — and 30 times more for output — $75 per million tokens. Meanwhile, for every one million tokens, GPT-4.1 charges $2 for input and $8 for output. Moonshot AI said on GitHub that developers can use K2 however they wish, with the only requirement that they display "Kimi K2" on the user interface if the commercial product or service has more than 100 million monthly active users, or makes the equivalent of $20 million in monthly revenue. Initial reviews of K2 on both English and Chinese social media have largely been positive, although there are some reports of hallucinations, a prevalent issue in generative AI, in which the models make up information. Still, K2 is "the first model I feel comfortable using in production since Claude 3.5 Sonnet," Pietro Schirano, founder of startup MagicPath that offers AI tools for design, said in a post on X. Moonshot has open sourced some of its prior AI models. The company's chatbot surged in popularity early last year as China's alternative to ChatGPT, which isn't officially available in the country. But similar chatbots from ByteDance and Tencent have since crowded the market, while tech giant Baidu has revamped its core search engine with AI tools. Kimi's latest AI release comes as investors eye Chinese alternatives to U.S. tech in the global AI competition. Still, despite the excitement about DeepSeek, the privately-held company has yet to announce a major upgrade to its R1 and V3 model. Meanwhile, Manus AI, a Chinese startup that emerged earlier this year as another DeepSeek-type upstart, has relocated its headquarters to Singapore. Over in the U.S., OpenAI also has yet to reveal GPT-5. Work on GPT-5 may be taking up engineering resources, preventing OpenAI from progressing on its open-source model, Counterpoint's Sun said, adding that it's challenging to release a powerful open-source model without undermining the competitive advantage of a proprietary model. Kimi K2 is not the company's only recent release. Moonshot launched a Kimi research model last month and claimed it matched Google's Gemini Deep Research 's 26.9 score and beat OpenAI's version on a benchmark called "Humanity's Last Exam." The Kimi research model even got a mention last week during Elon Musk's xAI release of Grok 4 — which scored 25.4 on its own on the "Humanity's Last Exam" benchmark, but attained a 44.4 score when allowed to use a variety of AI tools and web search. "Kimi-Researcher represents a paradigm shift in agentic AI," said Winston Ma, adjunct professor at NYU School of Law. He was referring to AI's capability of simultaneously making several decisions on its own to complete a complex task. "Instead of merely generating fluent responses, it demonstrates autonomous reasoning at an expert level — the kind of complex cognitive work previously missing from LLMs," Ma said. He is also author of "The Digital War: How China's Tech Power Shapes the Future of AI, Blockchain and Cyberspace."
